Course Description
The prescribing of clozapine is limited to treatment resistant schizophrenia due to concerns of agranulocytosis, resulting in frequent lab monitoring to reduce this risk. Patients with benign ethnic neutropenia (BEN) are prescribed clozapine less often without evidence to support this practice. This is a growing area of research that has the potential to improve clozapine prescribing for patients in whom it is currently being underutilized. This session focuses on how psychiatric pharmacists can overcome these barriers and provide the best care to patients presenting with BEN.
Learning Objectives
- Recall the underutilization of clozapine, particularly in Black patients and the prevalence of neutropenia in this population.
- Discuss characterization and impact of Benign Ethnic Neutropenia (BEN) on Absolute Neutrophil Count and how to determine BEN in patients.
- Describe cutting-edge data on the outcomes of clozapine in Black patients and those with BEN and the relative risk of neutropenia and severe neutropenia in this population.
Target Audience
If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.
Faculty
View biographical information
Deanna Kelly, PharmD, BCPP
MPower Professor, Interim Director, Maryland Psychiatric Research Center, Director, Treatment Research Program University of Maryland School of Medicine
Baltimore, MD
Deanna L. Kelly, Pharm.D., BCPP is Professor of Psychiatry at University of Maryland Baltimore School of Medicine where she recently was awarded the 3 year title of MPower Professor of Psychiatry, University of Maryland Strategic Partnership: MPowering the State. She also serves as an Affiliate Professor in the School of Pharmacy. She is currently Director and Chief of the Treatment Research Program at the Maryland Psychiatric Research Center (MPRC) and is serving as the Acting Director for 2021 of this prestigous institution. Dr. Kelly received her Bachelor of Science and Doctorate in Pharmacy at Duquesne University in Pittsburgh, PA. She completed residency training in psychiatric pharmacy practice at the University of Maryland in 1997 and became board certified in psychiatric pharmacy practice in 1998. Dr. Kelly has led and been involved in numerous clinical trials in schizophrenia and severe mental illness and has been active in psychopharmacology research for the past 24 years. Dr. Kelly has coauthored and authored 19 books and book chapters, published over 225 peer-reviewed articles, presented over 250 scientific posters and has given over 175 invited lectures. She has coauthored four editions of the book entitled “Pharmacologic Treatment of Schizophrenia.” She also authors the Schizophrenia chapter for “Pharmacotherapy, Principles and Practice.” She is Past President for the College of Psychiatric & Neurologic Pharmacists (CPNP), a Fellow of the American College of Neuropsychopharmacology (ACNP), currently serves as a clozapine content expert for the American Psychiatric Association SMI Adviser, and is a champion of clozapine use, women's health issues, inflammation and immune dysfunction in schizophrenia and for finding new treatments. In 2017 she was awarded the prestigious Maltz Prize for Innovative and Promising Schizophrenia Research by the Brain and Behavior Research Foundation. https://www.youtube.com/watch?v=y-9lOpPUdg0 Additionally, her work and scientific expertise has been featured in the New York Times, Women’s Day Magazine, Gluten-Free Living, Vice Media, Clinical Psychiatry News, Psychiatric News and Medscape Medical News. She can be found on twitter at @ProfDeannaK. More information can be found on her faculty page: http://www.medschool.umaryland.edu/profiles/Kelly-Deanna/
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Continuing Education Credit and Disclosures
Activity Date: 04/26/2022
ACPE Contact Hours: 1
ACPE Number: 0284-0000-22-043-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View planning committee disclosures
2022 Program Committee
|
Elayne D. Ansara, PharmD, BCPP, BCPS Clinical Pharmacy Specialist Veteran Health Indiana Indianapolis, IN No Relevant Financial Relationships to Disclose |
 Jolene R. Bostwick, PharmD, BCPP, BCPSProgram Administrative Chair Assistant Dean for Co-Curriculum and Professional Development & Clinical Professor University of Michigan College of Pharmacy Ann Arbor, MI No Relevant Financial Relationships to Disclose |
|
Bridget Bradley, PharmD, BCPP |
|
|
|
Chelsea N. Carr, PharmD, BCPP Advanced Practice Pharmacist - Psychiatry University of Maryland School of Pharmacy Catonsville, MD No Relevant Financial Relationships to Disclose |
|
Dana Chiulli, PharmD, BCPP Clinical Pharmacist - Mental Health VISN 06 Mental Health Clinical Resource Hub Savannah, GA No Relevant Financial Relationships to Disclose |
|
Jordan Cooler, PharmD, BCPP Clinical Assistant Professor University of South Carolina College of Pharmacy Columbia, SC No Relevant Financial Relationships to Disclose |
|
Bennett J. Doughty, PharmD, BCPP, BCPS |
|
Amber R. Douglass, PharmD, BCPS, BCPP Clinical Pharmacy Specialist - Mental Health VISN 1 Clinical Resource Hub - VA Connecticut Healthcare System West Haven, CT No Relevant Financial Relationships to Disclose |
Megan J. Ehret, PharmD, BCPP, MS |
|
Kristen N. Gardner, PharmD, BCPP |
|
Michelle L. Geier, PharmD, BCPP Psychiatric Clinical Pharmacist Supervisor San Francisco Department of Public Health San Francisco, CA External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Weitzman Institute Project ECHO Faculty |
|
Nicole Hahn, PharmD, BCACP Clinical Pharmacy Specialist - Neurology Kaiser Permanente Denver, CO No Relevant Financial Relationships to Disclose |
|
Kayla D. Johnson, PharmD, BCPP, BCPS Vanderbilt University Medical Center Thompsons Station, TN No Relevant Financial Relationships to Disclose |
|
Erin D. Knox, PharmD, BCPP Director of Experiential Education UCI School of Pharmacy & Pharmaceutical Sciences Irvine, CA Non-Financial Interests: Santa Ana Community College, Pharmacy Technology Program, Advisory Committee |
|
Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP Dean and Professor University of Montana, Skaggs School of Pharmacy Missoula, MT External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Editorial Board member: Continuum: Lifelong Learning in Neuroilogy, consultant for Lexicomp as a clinical specialist in neurology and psychiatry |
|
Melissa Mitchell, PharmD, BCGP, BCPP, BCPS Senior Clinical Pharmacist RUHS MC Moreno Valley , CA External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Neurocrine Speakers Bureau - Ingrezza, Janssen Speakers Bureau - Spravato, Otsuka - PsychU.org Speaker |
|
Thea R. Moore, PharmD, BCPP Associate Professor University of South Florida Tampa, FL No Relevant Financial Relationships to Disclose |
|
Lindsey Peters, PharmD, BCPS Associate Professor of Pharmacy Practice Ohio Northern University Ada, OH No Relevant Financial Relationships to Disclose |
|
Kristina Reinstatler, PharmD, BCPP, MBA Clinical Pharmacy Specialist UC Health University of Cincinnati Medical Center Cincinnati, OH Educational Grants, Research Grants or Contracts: HEALing Communities NIH grant- pharmacy lead Athens Cty, Ohio |
|
Michael D. Shuman, PharmD, BCPP Staff Pharmacist Central State Hospital Lousiville, KY No Relevant Financial Relationships to Disclose |
|
Taylor A. Thomas, PharmD, BCPP Clinical Pharmacy Specialist- Mental Health VA Northern Indiana Health Care System Fort Wayne, IN No Relevant Financial Relationships to Disclose |
|
Nina Vadiei, PharmD, BCPP Assistant Professor University of Arizona Colleges of Pharmacy and Medicine Tucson, AZ No Relevant Financial Relationships to Disclose |
Austin R. Campbell, PharmD, BCPPAll relevant relationships have been mitigated.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.